See today's BioWorld Science
To read the full story, subscribe or sign in.
Infection

Seed funding at Carver Biosciences supports work on CRISPR/Cas13 antivirals

Sep. 16, 2022
Carver Biosciences Inc., a company focused on the development of CRISPR/Cas13 antivirals, has closed a seed round of funding.
BioWorld Science Financings Infection Respiratory Private Seed